CTI BIOPHARMA CORP. CTIC Balance Sheet

Cti biopharma corp. (CTIC)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10	Sep'10	Jun'10	Dec'09
ASSETS
Current assets:
Cash and cash equivalents
81,149	31,144	34,917	35,364	40,593	36,439	52,911	65,374	104,633	27,218	52,800	74,740	33,283	44,002	61,595	76,707	104,641	128,182	46,355	54,864	44,395	70,933	29,910	33,184	50,601	71,639	27,176	28,568	44,314	50,436	14,289	14,755	27,380	47,052	45,212	38,887	22,649	17,268	64,534	37,811
Restricted cash
-	-	-	-	-	-	0	0	0	16,000	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short-term investments
0	2,522	11,815	18,297	21,657	30,599	28,005	27,450	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables from license and development services arrangements
-	-	137	356	821	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	0	0	-	180	480	311	378	620	559	666	282	422	880	1,272	2,011	1,177	613	503	235	540	782	768	-	-	-	-	-	-	-	-	-	-	-
Receivables from license and development services arrangements
-	-	-	-	-	13,679	269	696	775	1,278	2,490	259	120	7,778	1,329	6,568	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,674	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory, net
-	-	-	-	-	-	0	0	564	-	601	1,507	1,502	1,525	2,600	2,632	2,911	2,845	2,594	3,607	3,591	4,182	4,542	5,020	5,023	5,074	3,720	3,329	2,309	1,626	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
1,490	1,914	2,798	2,617	2,512	1,775	1,115	1,535	1,783	2,428	1,429	1,377	1,554	2,141	1,771	2,438	5,724	3,666	3,968	4,512	4,209	3,379	2,635	3,433	3,798	3,567	2,310	2,935	4,365	8,249	5,487	7,042	4,544	4,023	4,692	3,907	4,256	2,813	3,409	4,354
Total current assets
82,639	35,580	49,667	56,634	65,583	82,492	82,300	95,055	107,755	46,924	57,500	78,363	36,770	55,824	67,915	88,904	113,942	134,975	53,339	63,863	53,467	80,505	55,938	42,250	59,925	80,515	33,746	35,614	51,756	60,311	19,776	21,797	31,924	51,075	49,904	42,794	26,905	20,081	67,943	42,165
Property and equipment, net
1,102	1,235	1,381	1,516	1,653	1,793	1,938	2,084	2,233	2,365	2,534	2,642	2,830	3,023	3,220	3,412	3,617	3,718	3,950	4,148	4,391	4,646	4,841	5,000	5,148	5,478	5,838	6,294	6,643	6,785	7,734	8,376	4,261	3,604	4,309	4,517	3,426	3,114	3,507	3,430
Goodwill
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,064	17,064	17,064	17,064
Other Assets, Noncurrent
4,240	9,465	7,534	8,093	8,531	5,547	5,391	5,447	5,734	5,597	5,498	5,327	5,060	4,996	5,351	5,315	5,882	5,504	5,843	5,447	5,212	7,136	7,815	8,006	8,213	7,730	7,655	7,324	6,868	6,617	8,665	8,167	7,965	7,560	8,637	9,272	6,197	6,354	6,064	6,936
Total assets
87,981	46,280	58,582	66,243	75,767	89,832	89,629	102,586	115,722	54,886	65,532	86,332	44,660	63,843	76,486	97,631	123,441	144,197	63,132	73,458	63,070	92,287	68,594	55,256	73,286	93,723	47,239	49,232	65,267	73,713	36,175	38,340	44,150	62,239	62,850	56,583	53,592	46,613	94,578	69,595
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
905	0	2,965	1,095	1,116	4,498	2,078	3,715	2,194	2,588	2,020	4,013	11,878	7,227	13,662	14,031	17,712	10,584	13,381	11,180	10,279	6,356	6,297	6,444	4,604	5,051	10,364	11,344	10,837	12,065	11,936	13,522	5,491	5,750	6,564	7,307	6,037	6,506	6,187	7,297
Accrued expenses
6,565	11,606	11,036	10,251	8,534	12,852	15,667	14,243	14,774	13,890	14,971	22,076	20,903	24,765	22,832	16,984	18,954	22,133	17,455	17,440	14,607	19,734	15,350	11,906	9,543	9,469	7,854	9,890	9,934	10,209	9,067	9,108	8,928	11,064	10,420	15,452	11,008	8,368	9,003	14,807
Current portion of deferred revenue
-	-	-	-	-	-	441	-	-	912	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	247	368	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	991	702	483	541	-	5,445	10,355	-	-	-	-	-	-	-	-
Current portion of deferred revenue
-	-	-	-	-	-	-	806	915	-	872	1,321	304	103	224	467	646	578	652	847	779	826	903	899	1,043	1,010	-	-	-	-	-	-	-	-	-	-	-	-	-	80
Current portion of long-term debt
4,812	4,812	10,470	4,812	4,812	4,812	3,923	2,590	1,258	444	7,766	8,419	8,170	7,949	7,717	7,498	7,285	37,371	4,300	2,824	9,294	9,014	5,865	4,152	2,527	3,155	1,216	471	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
2,123	2,070	3,448	1,823	1,754	893	888	883	1,099	1,424	573	634	619	602	1,864	1,772	1,757	1,743	453	438	424	410	396	393	393	393	393	393	393	393	393	396	563	970	1,395	1,705	1,717	812	785	1,312
7.5% convertible senior notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,187	10,158	-
4% convertible senior subordinated notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38,515	40,363
Total current liabilities
14,405	18,488	27,919	17,981	16,216	23,055	22,997	22,237	20,240	19,258	26,202	36,463	41,874	40,646	46,299	40,752	46,354	72,409	36,488	33,097	35,383	36,340	28,811	23,794	18,110	20,069	20,529	22,581	21,705	22,667	26,841	33,381	14,982	17,784	30,808	36,778	41,070	25,873	64,648	63,859
Deferred revenue, less current portion
-	-	-	-	-	-	0	-	-	494	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue, less current portion
-	-	-	-	-	-	-	0	303	-	716	611	488	514	540	783	933	1,110	1,272	1,430	1,612	1,779	2,011	1,399	1,450	1,626	-	-	-	-	-	-	-	-	-	-	-	-	-	239
Long-term debt, less current portion
3,252	4,455	0	6,861	8,064	9,267	10,470	11,673	12,880	13,575	7,023	7,007	9,193	11,311	13,378	15,375	17,314	19,124	47,351	48,800	5,943	8,363	7,846	9,398	10,861	10,152	7,126	7,733	-	-	-	-	-	-	-	-	-	-	-	-
Long-term debt
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,066	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
4,295	5,407	4,472	6,416	6,900	4,571	4,800	5,028	5,252	5,469	3,179	3,331	3,478	3,615	3,752	3,966	4,097	4,141	5,538	5,659	5,775	5,882	5,989	6,092	6,179	5,657	5,736	5,814	5,935	4,641	5,768	6,449	3,520	2,985	3,088	3,442	4,206	1,010	1,179	1,861
7.5% convertible senior notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10,102
5.75% convertible senior notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,985	11,880	11,677
Total liabilities
21,952	28,350	32,391	31,258	31,180	36,893	38,267	38,938	38,675	38,796	37,120	47,412	55,033	56,086	63,969	60,876	68,698	96,784	90,649	88,986	48,713	52,364	44,657	40,683	36,600	37,504	33,391	36,128	35,706	27,308	32,609	39,830	18,502	20,769	33,896	40,220	45,276	38,868	77,707	87,738
Commitments and contingencies
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-
Common stock purchase warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	240	1,445	7,890	7,890	13,461	13,461	13,461	13,461	13,461	13,461	13,461	13,461	-	13,461	-	-	-	-	-	-
Stockholders' equity:
Authorized shares-333,333 Series 14 Preferred Stock, $1,000 stated value, 20,000 shares designated, 0 and 10,000 shares issued and outstanding at December 31, 2012 and 2011, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,736	-	-	-	-	-	-
Authorized shares - 150,000,000 Issued and outstanding shares - 112,639,301 and 109,823,748 at March 31, 2013 and December 31, 2012, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,875,284	-	1,810,035	1,784,646	-	1,744,801	1,721,284	1,679,531	1,579,866	-	-	-
Common stock purchase warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,461	-	13,461	13,461	13,461	13,461	12,255	626
Preferred stock
-	-	0	0	0	-	-	-	-	-	1,090	1,090	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common stock, no par value: Authorized shares - 81,500,000 and 41,500,000 at December 31, 2017 and 2016, respectively, Issued and outstanding shares - 42,969,494 and 28,228,602 at December 31, 2017 and 2016, respectively
-	-	-	-	-	-	-	-	-	-	2,220,448	2,219,067	2,172,061	2,170,300	2,168,237	2,163,174	2,161,013	2,157,300	2,053,087	2,031,982	2,028,975	2,023,949	1,957,696	1,953,916	1,942,989	1,933,305	1,900,746	1,877,099	-	1,872,885	-	-	-	-	-	-	-	-	-	-
Common stock, $0.001 par value per share: Authorized shares - 131,500,000 as of March 31, 2020 and December 31, 2019, Issued and outstanding shares - 73,681,593 and 57,979,725 as of March 31, 2020 and December 31, 2019, respectively
74	58	58	58	58	58	58	58	58	43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,753,473	-	-	-	-	1,545,324	1,539,510	1,418,931
Additional paid-in capital
2,315,810	2,299,186	2,297,931	2,296,637	2,295,275	2,294,025	2,292,560	2,290,017	2,288,977	2,223,388	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accumulated other comprehensive loss
-11,993	-11,993	-10,663	-10,622	-10,634	-10,643	-9,910	-9,898	-6,804	-6,272	-6,327	-6,437	-6,611	-6,655	-6,392	-6,451	-6,325	-6,952	-6,885	-6,886	-7,001	-6,499	-7,216	-8,440	-8,450	-8,429	-8,272	-7,953	-7,900	-8,273	-7,992	-7,919	-8,264	-8,035	-8,246	-8,841	-7,969	-8,159	-7,667	-8,412
Retained Earnings (Accumulated Deficit)
-2,275,749	-2,263,563	-2,255,375	-2,200,000	-2,200,000	-2,224,746	-2,225,592	-2,210,783	-2,199,447	-2,195,346	-2,181,080	-2,169,106	-2,170,154	-2,150,326	-2,143,954	-2,100,000	-2,095,005	-2,098,317	-2,069,480	-2,036,888	-2,004,291	-1,975,695	-1,931,501	-1,936,104	-1,908,705	-1,879,703	-1,889,899	-1,867,455	-1,849,444	-1,830,060	-1,811,030	-1,790,827	-1,732,231	-1,714,785	-1,696,917	-1,667,225	-1,576,643	-1,542,526	-1,526,919	-1,429,083
Total CTI stockholders' equity
28,142	23,688	31,951	40,745	50,342	58,694	57,116	69,394	82,784	21,813	34,131	44,614	-4,704	13,319	17,891	41,952	59,683	52,031	-23,278	-11,792	17,683	41,755	18,979	9,372	25,834	45,173	2,575	1,691	17,940	34,552	-8,987	-14,100	12,978	28,717	16,121	3,465	-4,746	-5,361	4,924	-18,564
Noncontrolling interest
-5,758	-5,758	-5,760	-5,760	-5,755	-5,755	-5,754	-5,746	-5,737	-5,723	-5,719	-5,694	-5,669	-5,562	-5,374	-5,197	-4,940	-4,618	-4,239	-3,736	-3,566	-3,277	-2,932	-2,689	-2,609	-2,415	-2,188	-2,048	-1,840	-1,608	-908	-851	-791	-708	-628	-563	-399	-355	-308	-205
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
22,384	17,930	26,191	34,985	44,587	52,939	51,362	63,648	77,047	16,090	28,412	38,920	-10,373	7,757	12,517	36,755	54,743	47,413	-27,517	-15,528	14,117	38,478	16,047	6,683	23,225	42,758	387	-357	16,100	32,944	-9,895	-14,951	12,187	28,009	15,493	2,902	-5,145	-5,716	4,616	-18,769
Total liabilities, mezzanine equity and stockholders' equity
87,981	46,280	58,582	66,243	75,767	89,832	89,629	102,586	115,722	54,886	65,532	86,332	44,660	63,843	76,486	97,631	123,441	144,197	63,132	73,458	63,070	92,287	68,594	55,256	73,286	93,723	47,239	49,232	65,267	73,713	36,175	38,340	44,150	62,239	62,850	56,583	53,592	46,613	94,578	69,595
Series X Preferred Stock
Preferred stock
43,645	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series O Preferred Stock
Preferred stock
0	0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock, $0.001 par value per share: Authorized shares - 33,333, Series N Preferred Stock, 0 shares and 575 shares issued and outstanding as of December 31, 2018 and 2017, respectively (Aggregate liquidation preference of $0 and $1,150 as of December 31, 2018 and 2017, respectively)
Preferred stock, Series O and N, $0.001 par value per share
-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-